Purpose: Surgical castration for metastatic prostate cancer is used less frequently than
medical castration yet costs less, requires less followup and may be associated with fewer …

Background Androgen deprivation therapy (ADT) is the gold standard for metastatic prostate
cancer, which can be achieved either by surgical or medical castration. In this study, we …

Background. Most patients with metastatic prostate cancer are endocrinologically treated
with LHRH agonist, but finally castration‐refractory and hormone‐refractory cancers occur …

Purpose: A prior report suggested that radical prostatectomy may confer a survival
advantage to patients with metastatic castration recurrent prostate cancer. Therefore, a …

Background Limited real‐world data exist on treatment patterns and outcomes in patients
with metastatic castration‐sensitive prostate cancer (mCSPC). Methods A retrospective …

Introduction Androgen deprivation therapy (ADT) remains the mainstay of treatment for
metastatic prostate cancer (mPCa) but is associated with significant morbidities …

Introduction: Over the past decade, the treatment of metastatic castration-sensitive prostate
cancer (mCSPC) has changed significantly. Current guidelines suggest the use of androgen …

5065 Background: Based on level 1 evidence of overall survival, ASCO/NCCN/AUA
guidelines uniformly recommend novel hormonal therapy (NHT) or chemotherapy (CHT) …

Purpose: This study provides a contemporary assessment of the treatment patterns, health
care resource utilization (HRU) and costs among metastatic castration-sensitive prostate …

e13592 Background: To date, there has been a paucity of information in the literature
describing the epidemiology of mCRPC within the prostate cancer population. We present a …